Coherus Oncology, Inc. Common Stock (CHRS)

Coherus BioSciences, Inc. is a biotechnology company focused on developing and commercializing biosimilar and biologic therapies. The company aims to provide affordable alternatives to existing biologic treatments in areas such as oncology, immunology, and ophthalmology. Coherus focuses on advanced biologic products and has a portfolio that includes biosimilars for popular reference drugs.

🚫 Coherus Oncology, Inc. Common Stock does not pay dividends

Company News

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
GlobeNewswire Inc. • Coherus Biosciences, Inc. • April 1, 2025

Coherus BioSciences announced it will repurchase $170 million of its convertible notes and divest its UDENYCA franchise to Intas Pharmaceuticals. The company plans to repurchase the remaining $60 million of convertible notes after the divestiture closes.

Pfizer: Seriously Undervalued At Peak Pessimism
Seeking Alpha • ALLKA Research • June 23, 2024

Pfizer's impressive financial results and promising clinical trials make it an undervalued asset in the pharmaceutical industry.

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 9, 2024

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

RNA
Why Coherus Biosciences Stock Tumbled on Thursday
The Motley Fool • [email protected] (Eric Volkman) • March 14, 2024

The company fell well short of expectations for its fourth quarter.

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga • Avi Kapoor • January 22, 2024

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Sagimet Biosciences Inc. (NASDAQ: SGMT) shares jumped 135% to $15.99 after the company announced denifanstat in the Phase 2b FASCINATE-2 clinical trial achieved statistically significant results on the primary and multiple secondary endpoints. Rail Vision Ltd. (NASDAQ: RVSN) surged 54.5% to $2.1173. Rail Vision said its main line system has successfully obtained formal certifications for critical European Union railway standards. Tenaya Therapeutics, Inc. (NASDAQ: TNYA) gained 40% to $5.36. Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) jumped 37% to $6.70. Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) surged 34.1% to $0.1376. Fisker Inc. (NYSE: FSR) shares gained 32.4% to $1.0450. Fisker filed a Form 8-K with the Securities and Exchange Commission regarding amendments with its 2025 convertible notes investor. Fitell Corporation (NASDAQ: FTEL) gained 28.5% to $2.25. Rumble Inc. (NASDAQ: RUM) surged 25.6% to $4.51 after the company announced a partnership with Barstool Sports. Eightco Holdings Inc. (NASDAQ: OCTO) jumped 24.9% to $0.5641. Digital World Acquisition Corp. (NASDAQ: DWAC) rose 24% to $32.70 after Ron DeSantis ended his presidential campaign. Digital World Acquisition Corp is the business combination partner of Trump Media & Technology Group. Fresh2 Group Limited (NASDAQ: FRES) gained 22.5% to $0.4900. Taoping Inc. (NASDAQ: TAOP) rose 21.3% to $1.0298. Coherus BioSciences, Inc. (NASDAQ: CHRS) shares climbed 17.1% to $2.8577 after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal. ChargePoint Holdings, ...